

# AMSER Case of the Month: October 2020

56-year-old male exertional dyspnea, orthopnea, and  
paroxysmal nocturnal dyspnea

Jaruwit Ty Rergyamdee, MS4

VCU School of Medicine Class of 2021

Dr. Peter Haar, M.D. & Dr. Leila Gharai, M.D.

VCU Medical Center, Department of Radiology



# Patient Presentation

- **HPI:** 56-year-old male with exertional dyspnea, orthopnea, and paroxysmal nocturnal dyspnea, weight gain (20 pounds over last 4 months), leg swelling, cough
- **Medical History:** Hypertension, hyperlipidemia, chronic kidney disease
- **Surgical History:** None
- **Medications:** Albuterol inhaler, cholecalciferol, fexofenadine, fluticasone nasal spray
- **Physical Exam:** Tachycardic, bibasilar crackles, abdomen mildly distended, +1 bilateral peripheral edema up to midshins bilaterally
- **Labs:** Cr 1.27 (unknown baseline), BNP 1,501

What Imaging Should We Order?

# Select the applicable ACR Appropriateness Criteria


Variant 1: Dyspnea due to heart failure. Ischemia not excluded.

Procedure	Appropriateness Category	SOE	Adult RRL	Peds RRL	Rating	Median	Final Tabulations								
							1	2	3	4	5	6	7	8	9
US echocardiography transthoracic resting	Usually appropriate		0 0 mSv	0 0 mSv [ped]	9	n/a	0	0	0	0	0	0	0	0	0
US echocardiography transthoracic stress	Usually appropriate		0 0 mSv	0 0 mSv [ped]	9	n/a	0	0	0	0	0	0	0	0	0
Radiography chest	Usually appropriate		⊕ <0.1 mSv	⊕ <0.03 mSv [ped]	9	n/a	0	0	0	0	0	0	0	0	0
Arteriography coronary with ventriculography	Usually appropriate		⊕⊕⊕ 1-10 mSv		8	n/a	0	0	0	0	0	0	0	0	0
MRI heart function and morphology without and with IV contrast	Usually appropriate		0 0 mSv	0 0 mSv [ped]	8	n/a	0	0	0	0	0	0	0	0	0
MRI heart with function and inotropic stress without and with IV contrast	Usually appropriate		0 0 mSv	0 0 mSv [ped]	7	n/a	0	0	0	0	0	0	0	0	0




This imaging modality was ordered by the ER physician

# Chest Radiograph (Unlabeled)



# Chest Radiograph (Labeled)



Bilateral  
reticulonodular  
opacities

Enlarged cardiac  
silhouette

Small bilateral pleural  
effusions

# Select the applicable ACR Appropriateness Criteria

Variant 1: Suspected pulmonary embolism. Intermediate probability with a negative D-dimer or low pretest probability.



Procedure	Appropriateness Category	SOE	Adult RRL	Peds RRL	Rating	Median	Final Tabulations								
							1	2	3	4	5	6	7	8	9
Radiography chest	Usually appropriate		☼ <0.1 mSv	☼ <0.03 mSv [ped]	9	n/a	0	0	0	0	0	0	0	0	0
CTA chest with IV contrast	May be appropriate		☼☼☼ 1-10 mSv	☼☼☼☼ 3-10 mSv [ped]	5	n/a	0	0	0	0	0	0	0	0	0
US duplex Doppler lower extremity	Usually not appropriate		○ 0 mSv	○ 0 mSv [ped]	3	n/a	0	0	0	0	0	0	0	0	0
US echocardiography transesophageal	Usually not appropriate		○ 0 mSv	○ 0 mSv [ped]	1	n/a	0	0	0	0	0	0	0	0	0
US echocardiography transthoracic resting	Usually not appropriate		○ 0 mSv	○ 0 mSv [ped]	2	n/a	0	0	0	0	0	0	0	0	0
Arteriography pulmonary with right heart catheterization	Usually not appropriate		☼☼☼☼ 10-30 mSv		1	n/a	0	0	0	0	0	0	0	0	0

Ordered to rule out PE!

This imaging modality was ordered by the ER physician




# CTA Chest (Unlabeled)






# CTA Chest (Labeled)

Mild cardiomegaly




Ground-glass opacities in upper lobes



Perilymphatic pulmonary nodules

Pleural effusions



# Rationale

- CTA Chest negative for PE
- Considering this, patient presentation likely due to non ischemic cardiomyopathy or congestive heart failure
- Evidence of pulmonary sarcoidosis also found on CTA Chest
- Due to suspicion for systemic disease, primary team proceeded with cardiac MRI....

# Select the applicable ACR Appropriateness Criteria


Variant 1: Dyspnea due to heart failure. Ischemia not excluded.

Procedure	Appropriateness Category	SOE	Adult RRL	Peds RRL	Rating	Median	Final Tabulations								
							1	2	3	4	5	6	7	8	9
US echocardiography transthoracic resting	Usually appropriate	0	0 mSv	0 0 mSv [ped]	9	n/a	0	0	0	0	0	0	0	0	0
US echocardiography transthoracic stress	Usually appropriate	0	0 mSv	0 0 mSv [ped]	9	n/a	0	0	0	0	0	0	0	0	0
Radiography chest	Usually appropriate	⊕	<0.1 mSv	⊕ <0.03 mSv [ped]	9	n/a	0	0	0	0	0	0	0	0	0
Arteriography coronary with ventriculography	Usually appropriate	⊕⊕⊕	1-10 mSv		8	n/a	0	0	0	0	0	0	0	0	0
MRI heart function and morphology without and with IV contrast	Usually appropriate	0	0 mSv	0 0 mSv [ped]	8	n/a	0	0	0	0	0	0	0	0	0
MRI heart with function and inotropic stress without and with IV contrast	Usually appropriate	0	0 mSv	0 0 mSv [ped]	7	n/a	0	0	0	0	0	0	0	0	0


This imaging modality was ordered by the primary team




# Cardiac MRI (Unlabeled)



Delayed contrast-enhanced  
Horizontal Long axis



Delayed contrast-enhanced  
Short axis view




Delayed contrast-enhanced  
Short axis view

# Cardiac MRI (Labeled)


Cardiomegaly

Significant patchy delayed myocardial enhancement of LV




Pleural effusions

Lytic osseous lesion



Granulomatosis of the spleen and liver



Final Dx:

Cardiac Sarcoidosis

# Cardiac Sarcoidosis

## Etiology:

Exposure to antigens (bacteria, environmental agents, etc.) → Immune response leading to non-caseating granuloma formation by helper T cells in cardiac myocytes

## Clinical Presentation:

- Congestive heart failure symptoms (shortness of breath, fatigue, edema)
- Arrhythmias (complete heart block, ventricular tachycardia), chest pain

## Differential Diagnosis:

- Ischemic Cardiomyopathy – Hx of longstanding CAD and possible MI, usually dilated cardiomyopathy picture (HFrEF)
- Constrictive Pericarditis – Hx of pericarditis or other risk factors (surgery, radiation, autoimmune), pericardial effusion or signs of tamponade, pericardial calcifications

# Cardiac Sarcoidosis - Diagnosis

**Serum Biomarkers:** ACE – no longer considered helpful diagnostically, may be used to monitor progression

**ECG:** Atrioventricular block, tachycardia, repolarization abnormalities

**Echocardiography:** LV systolic/diastolic dysfunction, pericardial effusion, valvular abnormalities

**Nuclear Medicine PET/CT:** May be useful in assessing disease activity

**MRI:** Imaging modality of choice – segmental myocardial motion abnormalities, increased myocardial T2 signal intensity, late gadolinium enhancement highly sensitive

**Histology:** Cardiac biopsy is also an option! Would show non-caseating granulomas in myocytes, “Invasive” and low sensitivity due to sampling error, not usually done



# Cardiac Sarcoidosis – Treatment

- Corticosteroids – slows progression of inflammation and fibrosis, doses of 60-80 mg of prednisone are generally prescribed
- Immunotherapy – methotrexate or azathioprine commonly prescribed for patients who cannot tolerate steroids or do not respond to steroids
- Pacemakers/Defibrillators – reserved for patients with impairing degrees of heart block and tachyarrhythmias, respectively
- Heart Transplant – an option for younger patients with severe disease, although rarely done

# Cardiac Sarcoidosis – Prognosis

## Prognosis

- Heart involvement is life-threatening- requires prompt treatment with steroids and immunosuppressive therapy
- Overall mortality not well defined- depends largely on the impairment of left ventricular function (symptomatic patient survival mostly limited to two years, another study records 5-year mortality of 40-60%)

# References:

1. Doughan, A., & Williams, B. (2006, February). Cardiac sarcoidosis. Retrieved July 28, 2020, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1860791/>
2. Dubrey, S., Bell, A., & Mittal, T. (2007, October). Sarcoid heart disease. Retrieved July 28, 2020, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600123/>
3. Kusano, K., & Satomi, K. (2016, February 01). Diagnosis and treatment of cardiac sarcoidosis. Retrieved July 28, 2020, from <https://heart.bmj.com/content/102/3/184.full>
4. Okada, D., Bravo, P., Vita, T., Agarwal, V., Osborne, M., Taqueti, V., . . . Blankstein, R. (2018, August). Isolated cardiac sarcoidosis: A focused review of an under-recognized entity. Retrieved July 28, 2020, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540795/>
5. Hulten, E., Aslam, S., Osborne, M., Abbasi, S., Bittencourt, M., & Blankstein, R. (2016, February). Cardiac sarcoidosis-state of the art review. Retrieved July 28, 2020, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731586/>